Moritz Glaser

CTNNB1 (β-catenin) mutations in NSCLC: clinicogenomic characteristics, prognostic value and implications for therapy

Moritz Glaser, Cornelia von Levetzow, Anna Rasokat, Darinka Prang, Lucia Nogova, Claudia Wömpner, Jaqueline Schmitz, Elisabeth Bitter, Inken Terjung, Anna Eisert, Rieke Fischer, Felix John, Sebastian Michels, Richard Riedel, Lea Ruge, Heather Scharpenseel, Wolfgang Schulte, Frank Beckers, Urte Sommerwerck, Udo Siebolts, Sabine Merkelbach-Bruse, Reinhard Buettner, Jürgen Wolf, Matthias Scheffler

Finding first clinical evidence to support experimental evidence that a subset of CTNNB1 mutations might confer resistance to EGFR-targeted therapy.

Preprint on MedRxiv (2025)

Data & Code on GitHub

ESM-Effect: An Effective Fine-Tuning Framework for Mutation Effect Prediction

Moritz Glaser, Johannes Brägelmann

Tackling functional effect prediction by fine-tuning PLMs on DMS data achieving SOTA performance and x4.7 faster training compared to multi-modal SOTA models. Also introducing a Benchmarking Framework testing on distinct sequence intervals to probe generalization and using the Bin-Mean-Error metric emphasizing prediction performance on rare Gain-of-Function mutations relevant to targeted cancer therapy.

Paper at MLGenX Workshop @ ICLR 2025

Preprint on BioRxiv (2025)

Code on GitHub

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients

Moritz Glaser, Anna Rasokat, Darinka Prang, Lucia Nogova, Claudia Wömpner, Jaqueline Schmitz, Elisabeth Bitter, Inken Terjung, Anna Eisert, Rieke Fischer, Felix John, Cornelia von Levetzow, Sebastian Michels, Richard Riedel, Lea Ruge, Heather Scharpenseel, Udo Siebolts, Sabine Merkelbach-Bruse, Reinhard Buettner, Jürgen Wolf and Matthias Scheffler

Comprehensive analysis of ROS1 mutations in NSCLC, providing insights into patient characteristics and treatment outcomes.

Published in Lung Cancer Journal (2023)